NL
KYMR icon

NVWM LLC’s Kymera Therapeutics KYMR Stock Holding History

NVWM LLC’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,191
Closed -$289K – 682
2024
Q4 		$289K Sell
7,191
-63
-0.9% -$2.85K 0.07% 187
2024
Q3 		$343K Hold
7,254
– – 0.09% 188
2024
Q2 		$217K Sell
7,254
-50
-0.7% -$1.73K 0.06% 188
2024
Q1 		$294K Buy
+7,304
New +$261K 0.08% 179

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

NVWM LLC's KYMR Position: Q1 2025 in Review

NVWM LLC sold out of Kymera Therapeutics (KYMR) in Q1 2025, closing a stake of 7,191 shares — an estimated $289K sold.

NVWM LLC first reported a position in KYMR in Q1 2024 and held it in 4 quarters. The position peaked at $343K in Q3 2024. 173 funds tracked by Wall St. Rank hold KYMR as of Q1 2025.

  • NVWM LLC reported no remaining Kymera Therapeutics position as of Q1 2025 after selling out during the quarter.
  • NVWM LLC sold 7,191 Kymera Therapeutics shares in Q1 2025, an estimated $289K.
  • NVWM LLC first reported a position in Kymera Therapeutics in Q1 2024 and held it in 4 quarters.
  • NVWM LLC's Kymera Therapeutics position peaked at $343K in Q3 2024.
  • 173 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2025.

Based on NVWM LLC's 13F filing for Q1 2025, filed 7 May 2025.